Pharma Focus Asia
Eppendorf Bioprocess Solutions

DISHMAN CARBOGEN AMCIS announces that its subsidiary, CARBOGEN AMCIS AG has entered into a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

Thursday, April 29, 2021

The company’s subsidiary, Carbogen Amcis AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a longstanding Japan based customer to build a site extension at the Bubendorf site in Switzerland.

The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filter drier. The facility is designed for highly potent manufacturing up to category 4 (OEL of 1 µg/m³ and lower).

“We are grateful for the trust our customer has placed in us by deciding to support the Bubendorf site extension. Their investment will enable the creation of a state-of-the art facility that will benefit them directly,” said Pascal Villemagne, VP sales and Marketing, CARBOGEN AMCIS. “This joint investment cements our working relationship over the long term and lays the foundation for a promising future.”

CARBOGEN AMCIS will produce exclusively for the signatory customer a complex highly potent drug component for a commercial antibody-drug-conjugate API.

“The production of this intermediate involves five Dishman Carbogen Amcis facilities around the world: three sites in Switzerland (Bubendof, Hunzenschwil and Aarau), one in the UK (Manchester) and one in China (Shanghai). The highly potent production element will take place in Bubendorf, in the new building extension.” commented Mark Griffiths, Director, Dishman Carbogen Amcis Limited. “We are thrilled and honoured to collaborate with our customer on this project to treat patients of need and also proud to demonstrate our ability to integrate our global supply chain network.”

Currently, the planning phase for the building extension is underway and the Company expects to commence operations in autumn 2022.

About Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited ( is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.

CARBOGEN AMCIS AG ( is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Limited., Ahmedabad, India.

For further information please visit the website

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACPHI Korea 2023Bora Pharmaceutical - A robust approach to analytical testing is essentialSelangor International Expo MEDIC 2023TFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile AppCPHI & PMEC China 20233rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023Pharma Regulatory Conclave 202320th Anniversary Hospitalog Asia 2023
Charles River Laboratories - Endosafe Compendial LAL Cartridge Technology